<DOC>
	<DOCNO>NCT01460719</DOCNO>
	<brief_summary>An open-label , multicenter study evaluate safety immunogenicity inactivate Varicella-Zoster Virus ( V212 ) vaccine participant hematologic malignancy ( HM ) currently receive anti-CD20 monoclonal antibody .</brief_summary>
	<brief_title>A Study Evaluate Safety Immunogenicity Inactivated Varicella-Zoster Virus ( VZV ) Vaccine Adults With HM Receiving Treatment With Anti-CD20 Monoclonal Antibodies ( V212-013 )</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Diagnosed HM receive treatment antiCD20 monoclonal antibody likely undergo hematopoietic cell transplant ( HCT ) . Has predict life expectancy â‰¥ 12 month . Has prior history varicella antibody VZV due exposure disease country disease common . All female participant childbearing potential must negative serum urine pregnancy test . A history allergic reaction vaccine component ( include gelatin ) anaphylactic/anaphylactoid reaction neomycin . Prior history HZ within 1 year enrollment . Prior receipt varicella zoster vaccine . Participant pregnant breastfeeding expect conceive within period 2 week prior enrollment throughout 6 month last vaccination dose . Any live virus vaccine administer scheduled period 4 week prior Dose 1 28 day postvaccination dose 4 . Any inactivated vaccine administer schedule within period 7 day prior , 7 day follow , dose study vaccine . Participant currently participate participate study investigational antiCD20 monoclonal antibody within 3 month sign informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>